While the overall Japanese pharma market is expected to remain at a similar overall value up to 2023, the oncology segment is expected to grow by five percent and by 2026, oncology is expected to represent one-fifth of the entire market. Cancer is one of the top three leading causes of death in Japan and the country's government is increasingly prioritising patient-oriented cancer treatment, most recently via the third version of a national Basic Plan to Promote Cancer Control.  

Made with Visme Infographic Maker